Results of Annual General Meeting
06/15/2022 - 01:40 PM
BOSTON --(BUSINESS WIRE)--
The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech Health” or the “Company”) was held at 11 a.m. EDT /4 p.m. BST on Wednesday, June 15, 2022 .
All of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a poll.
The results of the poll, incorporating the proxy votes lodged in advance of the meeting, are set out below.
Resolutions
For
%
Against
%
Withheld
Total votes cast
001. To approve the Company’s Annual Report and Accounts for year ended 31 December 2021
216,387,000
100.00
0
0.00
529,458
216,387,000
002. To approve the Directors’ Remuneration Report
186,654,636
86.20
29,871,462
13.80
390,360
216,526,098
003. To elect Ms. Sharon Barber-Lui as a director
216,911,434
100.00
2,288
0.00
2,736
216,913,722
004. To elect Dr. Raju Kucherlapati as a director
214,260,532
98.78
2,653,190
1.22
2,736
216,913,722
005. To elect Dr. John LaMattina as a director
208,222,704
95.99
8,691,018
4.01
2,736
216,913,722
006. To elect Ms. Kiran Mazumdar-Shaw as a director
186,900,260
86.16
30,013,462
13.84
2,736
216,913,722
007. To elect Dame Marjorie Scardino as a director
216,877,331
99.98
37,071
0.02
2,056
216,914,402
008. To elect Mr. Christopher Viehbacher as a director
190,417,512
87.78
26,496,210
12.22
2,736
216,913,722
009. To elect Dr. Robert Langer as a director
212,747,748
98.08
4,165,974
1.92
2,736
216,913,722
010. To elect Ms. Daphne Zohar as a director
216,905,622
100.00
8,100
0.00
2,736
216,913,722
011. To elect Dr. Bharatt Chowrira as a director
216,706,444
99.90
207,278
0.10
2,736
216,913,722
012. To reappoint KPMG LLP as Auditors of the Company
212,180,052
97.82
4,729,435
2.18
6,971
216,909,487
013. To authorize the Audit Committee to determine the Auditors' remuneration
212,703,757
98.06
4,211,701
1.94
1,000
216,915,458
014. To authorize the allotment of shares
212,364,212
97.90
4,551,246
2.10
1,000
216,915,458
015. To disapply pre-emption rights
216,589,860
99.85
324,482
0.15
2,116
216,914,342
016. To further disapply pre-emption rights for acquisitions and specified capital investments.
204,225,243
94.15
12,689,099
5.85
2,116
216,914,342
017. To authorize market purchase of own shares
216,386,703
99.76
528,755
0.24
1,000
216,915,458
018. To authorize general meetings to be called on not less than 14 clear days’ notice
212,326,728
97.88
4,588,730
2.12
1,000
216,915,458
Notes:
(1)
A vote “Withheld” is not a vote in law and is not counted in the calculation of the votes “For” or “Against” a resolution.
(2)
As at June 13, 2022 , the record date for the Annual General Meeting, the number of issued shares in the Company entitling the holders to attend and vote for or against all the resolutions at the AGM was 287,633,591 ordinary shares. This does not include 977,529 shares held in treasury by the Company. In accordance with the Company’s Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.
(3)
The full text of the resolutions may be found in the Notice of the Annual General Meeting, copies of which are available on both the Company’s website https://investors.puretechhealth.com/financials-filings/reports and on the National Storage Mechanism.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders.
This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 27 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization, as of the date of PureTech's most recently filed Annual Report and corresponding Form 6-K. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on unique insights in immunology and drug development.
For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2021 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com : https://www.businesswire.com/news/home/20220615005953/en/
PureTech
Investor Relations
IR@puretechhealth.com
Source: PureTech Health plc